We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
176
Dimensional Fund Advisors
Texas
$410K -$1.79K -42 -0.4%
Truist Financial
177
Truist Financial
North Carolina
$402K -$13.6K -319 -3%
CUAMC
178
China Universal Asset Management Company
China
$401K -$258K -6,051 -38%
Pathstone Holdings
179
Pathstone Holdings
New Jersey
$377K +$171K +3,998 +77%
Public Employees Retirement Association of Colorado
180
Public Employees Retirement Association of Colorado
Colorado
$368K – – –
I
181
InceptionR
California
$348K +$179K +4,188 +98%
BF
182
BOK Financial
Oklahoma
$342K +$67.5K +1,580 +23%
PRC
183
Pearl River Capital
Michigan
$315K +$328K +7,671 New
EFM
184
E Fund Management
China
$315K -$39.1K -915 -11%
VEA
185
Virtus ETF Advisers
New York
$314K -$28.2K -661 -8%
SIM
186
Sandia Investment Management
Massachusetts
$308K +$320K +7,500 New
XT
187
XTX Topco
Cayman Islands
$308K -$244K -5,726 -43%
Wealth Enhancement Advisory Services
188
Wealth Enhancement Advisory Services
Minnesota
$302K +$41.6K +975 +15%
Mitsubishi UFJ Asset Management
189
Mitsubishi UFJ Asset Management
Japan
$295K +$48K +1,123 +19%
SPS
190
Susquehanna Portfolio Strategies
Pennsylvania
$294K -$726K -17,000 -70%
US Bancorp
191
US Bancorp
Minnesota
$290K -$3.33K -78 -1%
AIA
192
Angeles Investment Advisors
California
$273K +$93.6K +2,193 +49%
YIH
193
Y-Intercept (HK)
Hong Kong
$269K -$196K -4,590 -41%
M&T Bank
194
M&T Bank
New York
$265K -$2.9K -68 -1%
OAM
195
Oppenheimer Asset Management
New York
$264K +$4.78K +112 +2%
Bank of Montreal
196
Bank of Montreal
Ontario, Canada
$259K +$262K +6,137 New
PCM
197
Prelude Capital Management
New York
$255K -$648K -15,188 -71%
HT
198
Headlands Technologies
Illinois
$252K +$236K +5,530 +931%
MSRPS
199
Maryland State Retirement & Pension System
Maryland
$251K – – –
LPL Financial
200
LPL Financial
California
$250K -$48.3K -1,131 -16%
6 7
8
9 10

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.